Guardian Pharmacy Services Reports 20% Revenue Growth and Net Income Turnaround in Q3 2025

Guardian Pharmacy Services, Inc. reported significant financial improvements in its latest 10-Q filing for the quarter ending September 30, 2025. The company achieved revenues of $377.4 million for the three months ended September 30, 2025, marking a 20% increase from $314.4 million in the same period of the previous year. For the nine-month period, revenues rose to $1.05 billion, an 18.1% increase from $889.8 million. The company also reported a net income of $9.6 million for the quarter, a substantial turnaround from a net loss of $105.8 million in the prior year, while net income for the nine months reached $27.7 million compared to a loss of $82.9 million.

The financial performance reflects a strategic shift following the company's initial public offering (IPO) in September 2024 and subsequent corporate reorganization. The filing noted that the company has expanded its customer base, serving approximately 204,000 residents across 8,200 long-term care facilities (LTCFs) in 38 states, up from 180,000 residents a year earlier. This growth was driven by both organic expansion and acquisitions, with the latter contributing $20 million to quarterly revenue growth. The number of prescriptions dispensed also increased from 6.4 million to 7.3 million year-over-year.

Operationally, Guardian Pharmacy has made significant strides in managing costs. Cost of goods sold for the three months ended September 30, 2025, was $302.7 million, a 19.4% increase from the previous year, but as a percentage of revenue, it decreased slightly from 80.6% to 80.2%. Selling, general, and administrative expenses saw a dramatic decline of 64.7% to $58.4 million, primarily due to a reduction in share-based compensation expenses that had inflated costs in the prior year. This reduction in expenses contributed to an operating income of $16.4 million for the quarter, compared to an operating loss of $104.6 million in the same period last year.

The company has also been active in acquisitions, completing several pharmacy operations in 2025, which are expected to enhance its market presence and operational efficiency. The total consideration for these acquisitions included cash payments and shares of Class B common stock, with the company recognizing $16.3 million in total purchase consideration. The acquisitions are anticipated to further bolster revenue and profitability in the coming quarters.

Looking ahead, Guardian Pharmacy Services remains optimistic about its growth trajectory, driven by its focus on long-term care facilities and the increasing demand for pharmacy services in this sector. The company plans to continue leveraging its scale and operational capabilities to enhance service delivery and expand its market share. With a solid cash position of $36.5 million as of September 30, 2025, and no outstanding debt under its credit facility, Guardian Pharmacy is well-positioned to meet its working capital needs and pursue further growth opportunities.